Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
The American Journal of Case Reports|April 10, 2013
Ovary involvement of diffuse large B-cell lymphomaRong Hu, Miao Miao, Rong Zhang, et al.
Environmental Toxicology|April 17, 2013
Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatmentHuihui Wang, Shuhua Xi, Zhuogang Liu, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 4, 2024
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosisXiaobin Wang, Yingqing Shi, Hua Shi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 28, 2012
Autophagy induced by FTY720 promotes apoptosis in U266 cellsAijun Liao, Rong Hu, Qihui Zhao, et al.
Advances in Therapy|October 22, 2014
Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patientsMaoFang Lin, Jian Hou, WenMing Chen, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 25, 2015
Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from ChinaJunru Liu, He Huang, Yan Li, et al.
Clinical Epigenetics|September 3, 2020
Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 studyLixin Wang, Jianmin Luo, Guofeng Chen, et al.
Cancer Medicine|June 23, 2023
Decitabine in patients with myelodysplastic syndromes: A multi-center, open-label, dose comparison trialHui Liu, Hao Jiang, Hongyan Tong, et al.
BMC Medicine|April 5, 2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm studyLugui Qiu, Zhongjun Xia, Chengcheng Fu, et al.
Leukemia Research|January 12, 2025
Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trialSuisui Kan, Hai Bai, Hui Liu, et al.
Pageof 7